Rome, Nov 15. (Adnkronos Health) – Communication between doctor and patient “is fundamental, but it becomes increasingly complex with the continuous advancements in medicine, especially in the field of diagnosis and personalized therapies.” This was highlighted by Francesco Perrone, president of the Aiom Foundation, commenting on the data from a survey presented at the XXVIII national Aiom congress which concludes today in Rome.
According to the survey, promoted by the Aiom Foundation, women with breast cancer and their caregivers still know little about precision oncology: only 32% of respondents know that liquid biopsy is a blood test that allows the identification of circulating tumor cells or molecules. 43% are unaware of targeted cancer therapies, and only 24% know what Molecular Tumor Boards are, which are multidisciplinary groups of specialists who evaluate cases and help identify the most appropriate therapies.
Perrone emphasizes the importance of “helping not only patients and their caregivers, but also citizens, to better understand the opportunities offered by research and precision medicine. Increasing awareness means giving patients more tools to manage their treatment journey and making dialogue with doctors simpler and more authentic. It is not an easy path, but it is fundamental.” With this objective, the Aiom Foundation collaborates with patient associations, including Andos, La Lampada di Aladino Ets, and Aimac, which is now part of the Foundation. “We are pleased to work together with these associations to increase patient awareness of advances in diagnosis and therapies. Knowing the possibilities offered by medicine means being able to participate more consciously in decisions about one’s treatment journey,” Perrone concludes.